ClinicalTrials.gg
CompletedNCT02015676Updated Mar 12, 2015Results posted

A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer

A Phase 1/2 interventional study of trastuzumab and paclitaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 1 site in Spain. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-03-12.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
69
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
167th of 366
69 · median 61
Started
2001
with 12 others
Phase 1/2
30 of 374
1 open now
Registered
213th of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 167th largest by enrollment of the 366 interventional ones that give a count, is one of 13 that started in 2001, is one of 30 in phase 1/2, and was the 213th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will define an optimal chemotherapy dose regimen of Myocet in combination with paclitaxel and intravenous Herceptin and will evaluate the efficacy and safety of this dose regimen in patients with metastatic or locally advanced breast cancer and HER2 overexpression. The anticipated time on study treatment is 3-12 months.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women 18-70 years of age;
  • or locally advanced breast cancer;
  • overexpression;
  • >= 1 .

Exclusion criteria

Exclusion Criteria:

  • prior treatment for advanced breast cancer;
  • prior treatment with Herceptin;
  • bone or central nervous system as the only site of disease;
  • history of another (except basal cell skin cancer and cancer in situ of the uterine cervix, and contralateral breast cancer) within 5 years of study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Trastuzumab, Myocet, Paclitaxel; Phase I

    Participants received an initial loading dose of trastuzumab 4 milligrams per kilogram (mg/kg), intravenously (IV), over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 40 mg/ square meter (m\^2), IV, every 3 weeks, from Week 1; if no dose limiting toxicity (DLT) was observed in greater than or equal to (≥) two-thirds (2/3) of cohort for 2 treatment cycles, the dose was increased to 50 mg/m\^2, IV, and continued for 6 cycles. Participants also received paclitaxel 60 mg/ m\^2, IV, once per week, from Week 19; if no DLT was observed in ≥ 2/3 of cohort for 2 treatment cycles, the dose was increased to 70 mg/m\^2, IV, and subsequently 80 mg/m\^2, IV, and continued until disease progression.

    Drug: trastuzumab · Drug: paclitaxel · Drug: Myocet

  • Experimental
    Trastuzumab, Myocet, Paclitaxel; Phase II

    Participants received an initial loading dose of trastuzumab 4 mg/kg, IV, over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 50 mg/m\^2, IV, every 3 weeks, from Week 1 for 6 cycles. Participants also received paclitaxel 80 mg/m\^2, IV, once per week, from Week 19 until disease progression.

    Drug: trastuzumab · Drug: paclitaxel · Drug: Myocet

Interventions

  • Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression

    Also known as: Herceptin

  • 60 mg/m\^2 IV weekly; dose increased to 70 mg/m\^2, and subsequently 80 mg/m\^2, after 2 treatment cycles with no evidence of DLT until disease progression

  • DrugMyocet

    40 mg/m\^2 IV weekly; dose increased to 50 mg/m\^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to World Health Organization (WHO) Handbook for Reporting Results of Cancer Treatment

    For measurable disease, CR was defined as the disappearance of all clinically detectable disease determined by 2 observations not less than 4 weeks apart; and PR was defined as a 50 percent (%) decrease in the sum of the products of the 2 greatest diameters of all measurable lesions by 2 observations not less than 4 weeks apart, and no appearance of new lesions or progression of any lesion. For immeasurable disease, CR was defined as the complete disappearance of all known disease for at least 4 weeks; and PR was defined as an estimated decrease in tumor size of 50% or more for at least 4 weeks.

    Time frame: Baseline (BL), Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)

Secondary outcomes

  1. Time to Disease Progression - Percentage of Participants With an Event

    Disease progression was defined as the time from the start of treatment to the date of the first recorded incident of disease progression, or the date of death due any cause. For measurable disease, disease progression was defined as a ≥25% increase in the sum of the products of diameters of 1 or more measurable lesions with a minimal area of greater than (\>)2 square centimeters (cm\^2), or the appearance of new lesions; and for malignant lesions with a minimal area of 2 cm\^2, an increase of ≥1 cm\^2. For immeasurable disease, disease progression was defined as the appearance of any new lesion not previously identified or an estimated increase of ≥50% in existent lesions.

    Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)

  2. Time to Disease Progression

    The median time, in months, from the start of treatment to disease progression event.

    Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)

  3. Time to Treatment Response - Percentage of Participants With an Event

    Treatment response was defined as the time from the start of treatment to the date of recorded CR or PR of measurable disease.

    Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)

  4. Time to Treatment Response

    The median time, in months, from the start of treatment to treatment response event.

    Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)

  5. Duration of Response - Percentage of Participants With an Event

    Duration of response was defined as the time from date CR was first recorded to the date progressive disease (PD) was first noted. For measurable disease, PD was defined as a ≥25% increase in the sum of the products of diameters of 1 or more measurable lesions with a minimal area of \>2 cm\^2, or the appearance of new lesions; and for malignant lesions with a minimal area of 2 cm\^2, an increase of ≥1 cm\^2. For immeasurable disease, PD was defined as the appearance of any new lesion not previously identified or an estimated increase of ≥50% in existent lesions.

    Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)

  6. Duration of Response

    The median time, in months, from enrollment to duration of response event to Week 52.

    Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)

  7. Time to Therapy Failure - Percentage of Participants With an Event

    Therapy failure was defined as the date of the start of therapy to the date of withdrawal due to adverse events, progressive disease/insufficient therapeutic response, death, failure to return, or refusal of treatment/lack of cooperation/withdrawal of consent. Participants were censored at the last dose of treatment if no event was recorded.

    Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)

  8. Time to Therapy Failure

    The median time, in months, from treatment start to therapy failure event. Participants were censored at the last date of treatment if no event was recorded.

    Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)

  9. Overall Survival (OS) - Percentage of Participants With an Event

    OS was defined as the time from the date of the start of treatment to the date of death or the last date the participant was known to be alive.

    Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)

  10. Overall Survival

    The time, in months, from the start of treatment to OS event. The mean survival time and it's standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

    Time frame: BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)

07

Results

Posted Mar 12, 2015

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab, Doxorubicin, Paclitaxel; Phase ITrastuzumab, Doxorubicin, Paclitaxel; Phase IITrastuzumab Doxorubicin, Paclitaxel; Phase I and Phase II
Started15486
Completed6143
Not completed9343
Withdrew: Adverse event2180
Withdrew: Lack of efficacy240
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject171
Withdrew: Administrative reasons031
Withdrew: Death010
Withdrew: Disease progression311

Outcome measures

PrimaryPercentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to World Health Organization (WHO) Handbook for Reporting Results of Cancer Treatment

For measurable disease, CR was defined as the disappearance of all clinically detectable disease determined by 2 observations not less than 4 weeks apart; and PR was defined as a 50 percent (%) decrease in the sum of the products of the 2 greatest diameters of all measurable lesions by 2 observations not less than 4 weeks apart, and no appearance of new lesions or progression of any lesion. For immeasurable disease, CR was defined as the complete disappearance of all known disease for at least 4 weeks; and PR was defined as an estimated decrease in tumor size of 50% or more for at least 4 weeks.

Time frame:
Baseline (BL), Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to World Health Organization (WHO) Handbook for Reporting Results of Cancer Treatment
percentage of participantsTrastuzumab, Doxorubicin, Paclitaxel; Phase II
CR51.85
PR46.30
SecondaryTime to Disease Progression - Percentage of Participants With an Event

Disease progression was defined as the time from the start of treatment to the date of the first recorded incident of disease progression, or the date of death due any cause. For measurable disease, disease progression was defined as a ≥25% increase in the sum of the products of diameters of 1 or more measurable lesions with a minimal area of greater than (\>)2 square centimeters (cm\^2), or the appearance of new lesions; and for malignant lesions with a minimal area of 2 cm\^2, an increase of ≥1 cm\^2. For immeasurable disease, disease progression was defined as the appearance of any new lesion not previously identified or an estimated increase of ≥50% in existent lesions.

Time frame:
BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Reported as:
Number · percentage of participants
Time to Disease Progression - Percentage of Participants With an Event
percentage of participantsTrastuzumab, Doxorubicin, Paclitaxel; Phase II
Time to Disease Progression - Percentage of Participants With an Event40.74
SecondaryTime to Disease Progression

The median time, in months, from the start of treatment to disease progression event.

Time frame:
BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Reported as:
Median · months
Time to Disease Progression
monthsTrastuzumab, Doxorubicin, Paclitaxel; Phase II
Time to Disease Progression43.3018 (24.0821 to NA)
SecondaryTime to Treatment Response - Percentage of Participants With an Event

Treatment response was defined as the time from the start of treatment to the date of recorded CR or PR of measurable disease.

Time frame:
BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Reported as:
Number · percentage participants
Time to Treatment Response - Percentage of Participants With an Event
percentage participantsTrastuzumab, Doxorubicin, Paclitaxel; Phase II
Time to Treatment Response - Percentage of Participants With an Event98.15
SecondaryTime to Treatment Response

The median time, in months, from the start of treatment to treatment response event.

Time frame:
BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Reported as:
Median · months
Time to Treatment Response
monthsTrastuzumab, Doxorubicin, Paclitaxel; Phase II
Time to Treatment Response1.87269 (1.83984 to 1.93840)
SecondaryDuration of Response - Percentage of Participants With an Event

Duration of response was defined as the time from date CR was first recorded to the date progressive disease (PD) was first noted. For measurable disease, PD was defined as a ≥25% increase in the sum of the products of diameters of 1 or more measurable lesions with a minimal area of \>2 cm\^2, or the appearance of new lesions; and for malignant lesions with a minimal area of 2 cm\^2, an increase of ≥1 cm\^2. For immeasurable disease, PD was defined as the appearance of any new lesion not previously identified or an estimated increase of ≥50% in existent lesions.

Time frame:
BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Reported as:
Number · percentage of participants
Duration of Response - Percentage of Participants With an Event
percentage of participantsTrastuzumab, Doxorubicin, Paclitaxel; Phase II
Duration of Response - Percentage of Participants With an Event39.62
SecondaryDuration of Response

The median time, in months, from enrollment to duration of response event to Week 52.

Time frame:
BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Reported as:
Median · months
Duration of Response
monthsTrastuzumab, Doxorubicin, Paclitaxel; Phase II
Duration of Response41.1006 (20.9610 to NA)
SecondaryTime to Therapy Failure - Percentage of Participants With an Event

Therapy failure was defined as the date of the start of therapy to the date of withdrawal due to adverse events, progressive disease/insufficient therapeutic response, death, failure to return, or refusal of treatment/lack of cooperation/withdrawal of consent. Participants were censored at the last dose of treatment if no event was recorded.

Time frame:
BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Reported as:
Number · percentage of participants
Time to Therapy Failure - Percentage of Participants With an Event
percentage of participantsTrastuzumab, Doxorubicin, Paclitaxel; Phase II
Time to Therapy Failure - Percentage of Participants With an Event81.48
SecondaryTime to Therapy Failure

The median time, in months, from treatment start to therapy failure event. Participants were censored at the last date of treatment if no event was recorded.

Time frame:
BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Reported as:
Median · months
Time to Therapy Failure
monthsTrastuzumab, Doxorubicin, Paclitaxel; Phase II
Time to Therapy Failure24.0821 (17.5113 to 35.6797)
SecondaryOverall Survival (OS) - Percentage of Participants With an Event

OS was defined as the time from the date of the start of treatment to the date of death or the last date the participant was known to be alive.

Time frame:
BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Reported as:
Number · percentage of participants
Overall Survival (OS) - Percentage of Participants With an Event
percentage of participantsTrastuzumab, Doxorubicin, Paclitaxel; Phase II
Overall Survival (OS) - Percentage of Participants With an Event3.70
SecondaryOverall Survival

The time, in months, from the start of treatment to OS event. The mean survival time and it's standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Time frame:
BL, Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years)
Reported as:
Mean · months
Overall Survival
monthsTrastuzumab, Doxorubicin, Paclitaxel; Phase II
Overall Survival7.6909 ± 0.1338

Adverse events

Collected over BL, and Weeks 7, 13, 19, every 8 weeks thereafter until end of study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab, Doxorubicin, Paclitaxel; Phase I & II—26/69 (37.7%)63/69 (91.3%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventTrastuzumab, Doxorubicin, Paclitaxel; Phase I & II
Febrile neutropeniaGeneral disorders12/69
Cardiac failure NOSCardiac disorders2/69
CoughRespiratory, thoracic and mediastinal disorders2/69
DyspnoeaRespiratory, thoracic and mediastinal disorders2/69
Diarrhoea NOSGastrointestinal disorders2/69
Pneumonia NOSRespiratory, thoracic and mediastinal disorders2/69
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders1/69
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/69
Intestinal obstruction NOSGastrointestinal disorders1/69
EndocarditisInfections and infestations1/69
Most frequent other events
Showing 10 of 176
Most frequent other events
EventTrastuzumab, Doxorubicin, Paclitaxel; Phase I & II
AlopeciaSkin and subcutaneous tissue disorders54/69
Mucosal inflammation NOSRespiratory, thoracic and mediastinal disorders40/69
NauseaGastrointestinal disorders36/69
AstheniaGeneral disorders35/69
Diarrhoea NOSGastrointestinal disorders29/69
Vomiting NOSGastrointestinal disorders26/69
Nail disorder NOSGeneral disorders23/69
PyrexiaGeneral disorders23/69
NeutropeniaBlood and lymphatic system disorders21/69
Oedema peripheralGeneral disorders19/69

Baseline characteristics

Age, Continuous
Age, Continuous(years)Trastuzumab, Doxorubicin, Paclitaxel; Phase ITrastuzumab, Doxorubicin, Paclitaxel; Phase IITrastuzumab, Doxorubicin, Paclitaxel; Phase II and IITotal
Mean54.73 ± 12.4252.98 ± 12.3344.33 ± 15.3652.61 ± 12.70
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab, Doxorubicin, Paclitaxel; Phase ITrastuzumab, Doxorubicin, Paclitaxel; Phase IITrastuzumab, Doxorubicin, Paclitaxel; Phase II and IITotal
Female1548669
Male0000
08

Study locations

1 site
  • Madrid, 28027, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2001, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2013
First posted
Dec 19, 2013
Start
Jul 2001
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Mar 12, 2015
Last update
Mar 12, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02015676
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 19, 2013
Start date
Jul 2001
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Mar 12, 2015
Last update
Mar 12, 2015

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab · Paclitaxel · Doxorubicin

Start the discussion